News
Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss: Study
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with ...
Postmenopausal women on tirzepatide show lower weight loss than those typically seen with the obesity drug, but weight loss ...
1d
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...
In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...
1d
HealthDay on MSNENDO: Superior Weight Loss Seen With Tirzepatide and Menopausal Hormone Therapy UseIn postmenopausal women with overweight or obesity receiving tirzepatide, use of menopausal hormone therapy (MHT) is ...
Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...
3d
News-Medical.Net on MSNTirzepatide reduces obesity-associated breast cancer growth in mouse modelThe anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...
Tirzepatide reduces breast tumor growth in obese mice while improving metabolic health, offering hope as a dual-action cancer ...
Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...
Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...
By Nancy Lapid (Reuters) -GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results